Phillip P. Chan, serving as both Chief Executive Officer and a director at Cytosorbents Corp (NASDAQ:CTSO), has executed a series of open market transactions to acquire the company's common stock. The total value of these purchases reached $104,897, conducted across two distinct dates in mid-June 2026.
The initial phase of this buying activity occurred on June 12, 2026. During this session, Mr. Chan acquired 251,136 shares. The weighted average price for this block was recorded at $0.40 per share. The execution of these purchases involved multiple transactions, with the specific fill prices ranging from $0.3885 to $0.40 per share.
Three days later, on June 15, 2026, Mr. Chan executed a secondary purchase. He acquired an additional 10,333 shares. This second tranche carried a weighted average price of $0.43 per share. Similar to the earlier purchase, this acquisition was split across multiple transactions, with individual prices ranging from $0.4307 to $0.4388 per share.
These recent acquisitions occur while the company's equity is trading near its 52-week low of $0.37. Over the trailing twelve-month period, the stock has experienced a decline of 60%. Market analysis indicates that the shares are currently trading below their calculated Fair Value, suggesting a potential undervaluation at present price levels.
Following the completion of these transactions, Mr. Chan's direct holdings in Cytosorbents Corp have increased. He now holds a total of 1,744,432 shares. This total position comprises 1,422,832 shares of common stock directly owned. The remaining portion of his holdings consists of Restricted Stock Units (RSUs) subject to specific vesting conditions.
The RSU holdings include grants issued on March 15, 2018; February 24, 2017; June 7, 2016; and April 8, 2015. These specific units are structured to settle into shares only upon the occurrence of a "Change In Control" event within the company.
Additionally, Mr. Chan holds 105,600 RSUs granted on August 8, 2025. These units are scheduled to vest in equal installments at the first and second-year anniversaries of the grant date. This vesting is contingent upon his continued employment and service with the company.
The timing of these insider purchases coincides with the release of Cytosorbents' first-quarter earnings for 2026. The reported financial results did not align with analyst forecasts. The company reported a loss per share of $0.05, which exceeded the anticipated loss of $0.04 per share.
Revenue performance also fell short of projections. The company reported top-line revenue of $8.9 million, missing the consensus forecast of $9.23 million. These results highlight ongoing challenges in aligning operational outcomes with market expectations.
Despite the missed financial targets, the company maintains its focus on strategic objectives. Investors are closely monitoring these developments as they assess the firm's future performance trajectory.